Company Overview - Alignment Healthcare, Inc. is focused on providing high-quality, low-cost care for its Medicare Advantage members, emphasizing a mission-driven approach to senior care [2] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology named AVA to deliver coordinated care [2] - Alignment Healthcare is based in California and partners with nationally recognized local providers to enhance its service offerings [2] Upcoming Events - Alignment Healthcare will present at the BofA Securities Healthcare Conference on May 14, 2025, at 2:20 p.m. PDT [1] - A webcast and replay of the presentation will be accessible on the company's investor relations website [1]

Financial Performance - The company reported a net loss, highlighting challenges in achieving profitability amid increasing expenses[12]. - The net loss attributable to Alignment Healthcare, Inc. for 2024 was $128.0 million, compared to a net loss of $148.0 million in 2023, indicating a 13.5% improvement[458]. - The net loss for 2024 was $128,071, a reduction from a net loss of $148,173 in 2023, indicating an improvement in financial performance[473]. - The total stockholders' equity decreased to $100.9 million in 2024 from $158.1 million in 2023, a decline of 36.2%[456]. - The company recorded a net income tax expense of $21 for the year ended December 31, 2024, compared to a benefit of $(22) in 2023[564]. - The equity in loss of subsidiary was $125,892 in 2024, compared to $147,529 in 2023, showing a decrease in losses from subsidiaries[616]. Revenue and Expenses - Total revenues for the year ended December 31, 2024, were $2,703.6 million, representing a 48.3% increase from $1,823.6 million in 2023[458]. - Medical expenses for 2024 amounted to $2,406.9 million, up 48.2% from $1,622.6 million in 2023[458]. - Premium revenue for 2024 was $2,666,813, a substantial increase from $1,668,131 in 2023, demonstrating strong growth in the Medicare Advantage sector[476]. - Capitation revenue for 2024 was $5,118, a decrease from $132,802 in 2023, indicating a shift in revenue sources[476]. - The total incurred medical expenses for the current year reached $832,819 million in 2024, significantly higher than the $492,315 million incurred in 2023[551]. - Medical expenses payable rose to $289.8 million in 2024, up 40.9% from $205.4 million in 2023[456]. Assets and Liabilities - Total current assets increased to $661.6 million in 2024 from $483.5 million in 2023, reflecting a growth of 36.8%[456]. - The company's total assets reached $782.1 million as of December 31, 2024, compared to $591.9 million in 2023, marking a 32.2% increase[456]. - Long-term debt increased significantly to $321.4 million in 2024 from $161.8 million in 2023, representing a 98.7% rise[456]. - The total liabilities rose to $325,182 in 2024 from $1,319 in 2023, reflecting a substantial increase due to new debt issuance[612]. - Cash and cash equivalents at the end of 2024 were $432,859, compared to $204,904 at the end of 2023, reflecting a significant increase in liquidity[465]. Investments and Financial Instruments - As of December 31, 2024, the company held $71.1 million in U.S. Treasury bills classified as held to maturity[436]. - The carrying value of U.S. Treasury bills decreased from $117,337 million in 2023 to $71,120 million in 2024, reflecting a significant reduction in investments[538]. - The company had $469,373 million in excess of FDIC-insured limits as of December 31, 2024, compared to $316,977 million in 2023, indicating increased cash reserves[520]. - As of December 31, 2024, the company had restricted investments in U.S. Treasury bills amounting to $1,033 million and certificates of deposits totaling $2,321 million[542]. Operational Efficiency and Management - The company is focused on maintaining high ratings on the Five Star Quality Rating System to enhance its competitive position[12]. - The company entered into a management services and risk management agreement with a third-party healthcare company in 2024, which is expected to enhance operational efficiency[481]. - The company’s management team has limited experience managing a public company, which may impact future performance[12]. Regulatory and Compliance - Medicare Advantage Plans in California, North Carolina, Nevada, Arizona, Texas, and Florida are subject to a minimum annual medical loss ratio (MLR) of 85%[486]. - The company is required to remit a portion of premiums back to the federal government if the minimum MLR is not met, although amounts payable were immaterial as of December 31, 2024[486]. - The Inflation Reduction Act is expected to have an immaterial impact on the company's consolidated financial statements at December 31, 2024, with provisions set to take effect over the next seven years[511]. Shareholder and Equity Information - The weighted-average common shares outstanding increased to 190.8 million in 2024 from 186.2 million in 2023, an increase of 2.8%[458]. - As of December 31, 2024, there were 8,762,481 stock options outstanding with a weighted-average exercise price of $16.97[571]. - The company granted 6,994,001 restricted stock units (RSUs) in 2024, with unvested and outstanding RSUs totaling 13,344,685 at year-end[575]. - Total equity-based compensation expense was $71,132, an increase from $66,835 in 2023[580]. Legal and Contingent Liabilities - The company accrued a potential liability of $913 related to a class action lawsuit as of December 31, 2024[599].

Financial Performance - Total revenue for Q4 2024 was $701.2 million, up 50.7% year-over-year, while full-year revenue was $2,703.6 million, up 48.3% year-over-year[8] - Adjusted EBITDA for Q4 2024 was $1.4 million, with a net loss of $(31.1) million, compared to a net loss of $(47.2) million in Q4 2023[8] - Adjusted gross profit for Q4 2024 was $87.9 million, compared to $49.2 million in Q4 2023[8] - Total revenues for 2024 reached $2,703,561, a 48.3% increase from $1,823,630 in 2023[17] - Earned premiums increased to $2,671,931 in 2024, up 48.3% from $1,800,933 in 2023[17] - Total expenses for 2024 were $2,805,116, a 43.8% increase compared to $1,951,447 in 2023[17] - Net loss for 2024 was $128,071, an improvement from a net loss of $148,173 in 2023[19] - Net loss per share attributable to Alignment Healthcare, Inc. improved to $(0.67) in 2024 from $(0.79) in 2023[17] Membership Growth - Health plan membership reached 189,100 as of December 31, 2024, representing a 58.6% increase year-over-year[7] - The midpoint of 2025 health plan membership guidance was raised by 2,000 due to strong open enrollment momentum[7] Cash and Assets - Cash and cash equivalents increased to $432.9 million as of December 31, 2024, up from $202.9 million in 2023[16] - Cash and cash equivalents at the end of 2024 were $432,859, compared to $204,954 at the end of 2023[20] - Total assets grew to $782.1 million as of December 31, 2024, compared to $591.9 million in 2023[16] Debt and Financial Position - Long-term debt increased to $321.4 million as of December 31, 2024, up from $161.8 million in 2023[16] - Net cash provided by operating activities was $34,770 in 2024, a recovery from a cash used of $(59,187) in 2023[20] Future Guidance - The company introduced 2025 revenue guidance of $3.72 billion to $3.78 billion, indicating a year-over-year growth of 37.6% to 39.6%[7] Operational Metrics - Medical benefits ratio based on adjusted gross profit was 87.5% for Q4 2024, compared to 88.8% for the full year 2024[8] - Adjusted EBITDA is used by management to assess operating performance, although specific figures were not disclosed in the provided content[23] - Medical Benefits Ratio (MBR) is calculated by dividing total medical expenses by total revenues, although specific MBR figures were not provided[25] Strategic Initiatives - The company plans to continue evaluating acquisition opportunities as part of its business strategy[22]

Financial Data and Key Metrics Changes - Health plan membership reached 182,300 members, representing approximately 58% year-over-year growth, surpassing the year-end guidance of 178,000 to 180,000 members [7][26] - Total revenue for Q3 2024 was $692 million, growing approximately 52% year-over-year, and 62% excluding ACO REACH, marking the highest revenue growth quarter as a publicly traded company [8][27] - Adjusted gross profit was $81 million, with a consolidated Medical Benefit Ratio (MBR) of 88.4%, leading to adjusted EBITDA of positive $6 million for the quarter [8][31] - For the full year 2024, revenue is expected to be between $2.67 billion and $2.68 billion, with adjusted gross profit between $282 million and $297 million [34] Business Line Data and Key Metrics Changes - The Care Anywhere clinical model contributed to managing care and controlling costs while achieving nearly 60% membership growth year-over-year [11] - 98% of health plan members are in plans rated 4-stars or above for 2025, with significant performance in California HMO contracts [12][13] - Adjusted SG&A for Q3 was $75 million, an increase of 8% year-over-year, but as a percentage of revenue excluding ACO REACH, it declined from 16.2% to 10.8% [30][31] Market Data and Key Metrics Changes - The company is positioned to benefit from CMS's changes that reward health plans delivering better care and value to seniors, creating opportunities for growth [9][10] - The California HMO contract has maintained a 4-star rating for eight consecutive years, while the Nevada and North Carolina contracts retained their 5-star ratings [12][13] Company Strategy and Development Direction - The company is focusing on profitability and directing capital towards markets with the greatest competitive advantage and highest return on investment [19] - For 2025, the company anticipates at least 20% growth and is confident in achieving consensus adjusted EBITDA of approximately $40 million [23][40] - The Medicare Advantage industry is seen as being at an inflection point, requiring population health management capabilities and consumer-centric technology [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong star ratings and the ability to manage costs while growing quickly, reinforcing confidence in the 2025 outlook [31][40] - The company is optimistic about the upcoming year, expecting continued growth and margin expansion opportunities [20][40] Other Important Information - The company ended Q3 with $381 million in cash and investments, with expectations for year-end parent cash to be approximately the same or higher [32] - Adjusted EBITDA profitability has been achieved for two consecutive quarters, highlighting the company's ability to manage costs effectively [31] Q&A Session Summary Question: What are the ongoing investments in local market relations with providers and brokers? - The company is investing in provider operations and automating workflows to enhance collaboration with IPAs, aiming for better outcomes [42][44] Question: What factors contributed to the strong membership growth? - The disciplined bid process and investments in member experience have led to significant growth, with a focus on balancing growth and margin [46][48] Question: How does the company view the MLR changes and their impact on 2025? - The company is confident that the elevated MLR in Q4 will not affect their 2025 outlook, as strong utilization performance supports their assumptions [56][57] Question: What is the strategy regarding capitated contracts and Part D? - There are no changes expected in the structure of capitated contracts for 2025, and Part D is anticipated to be a tailwind for overall MLR next year [100][102] Question: How is the company addressing CAHPS scores and access to care? - The company is focusing on improving care routing and access to specialists, integrating IPAs into their workflows to enhance member experience [91][92]

Table of Contents _______________________________________ _______________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ALHC The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

EXHIBIT 99.1 Alignment Healthcare Reports Third Quarter 2024 Results Reports $692.4 million in total revenue, up 51.6% year-over-year Increases Medicare Advantage membership, up 57.7% year-over-year to approximately 182,300 members, beating third-quarter and year-end expectations One of seven Medicare Advantage Prescription Drug contracts nationally to earn 5- out of 5 stars from the Centers for Medicare & Medicaid Services (CMS), with 98% of company's Medicare Advantage members in plans rated 4-stars or hi ...

Alignment Healthcare, Inc. (NASDAQ:ALHC) Q2 2024 Earnings Conference Call August 1, 2024 5:30 PM ET Company Participants John Kao - Founder & Chief Executive Officer Thomas Freeman - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Whit Mayo - Leerink Partners Michael Ha - Baird Jess Tassan - Piper Sandler Jared Haase - William Blair Adam Ron - Bank of America Scott Fidel - Stephens Ryan Langston - TD Cowen Andrew Mok - Barclays Operator Good afternoon and welcome to Alignmen ...

Financial Performance - Total revenues for Q2 2024 reached $681.3 million, a 47.3% increase from $462.4 million in Q2 2023[20] - Earned premiums for Q2 2024 were $674.1 million, up 47.5% from $456.9 million in Q2 2023[20] - Medical expenses for Q2 2024 totaled $605.3 million, representing a 47.3% increase compared to $410.6 million in Q2 2023[20] - The net loss for Q2 2024 was $24.0 million, slightly improved from a net loss of $28.5 million in Q2 2023[20] - Adjusted EBITDA for the three months ended June 30, 2024, was $6,034,000, a significant improvement of 393.6% from a loss of $2,055,000 in the same period of 2023[157] - The loss from operations for the three months ended June 30, 2024, was $18,382,000, a 22.3% improvement from a loss of $23,659,000 in the same period of 2023[157] - Net cash provided by operating activities for the six months ended June 30, 2024, was $17,291,000, a significant decrease from $122,287,000 for the same period in 2023[33] - The company recorded a net change in cash of $136.1 million for the six months ended June 30, 2024, compared to a decrease of $14.3 million for the same period in 2023[196] Assets and Liabilities - Total current assets increased to $599.1 million as of June 30, 2024, compared to $483.5 million at December 31, 2023, reflecting a 23.9% growth[18] - Total liabilities rose to $591.5 million as of June 30, 2024, up from $433.8 million at December 31, 2023, indicating a 36.3% increase[18] - The company reported a total stockholders' equity of $124.8 million as of June 30, 2024, down from $158.1 million at December 31, 2023[18] - The company’s total assets as of June 30, 2024, were $1,074,303,000, compared to $1,007,794,000 as of June 30, 2023, reflecting an increase of approximately 6.6%[29] Membership and Market Expansion - Health plan membership increased to 175,100 as of June 30, 2024, representing a 56.1% growth compared to 112,200 in the same period of 2023[157] - The company expanded into 14 new markets in 2023 and one new market in California in 2024, focusing on areas with significant senior populations[148] - The company holds a 4% market share in its existing 53 counties, indicating significant growth opportunities in the Medicare Advantage market[147] Expenses - Selling, general, and administrative expenses for Q2 2024 were $87.9 million, a 25.3% increase from $70.2 million in Q2 2023[20] - Medical expenses payable rose to $315,369 million as of June 30, 2024, up from $205,399 million as of December 31, 2023, indicating a 53.5% increase[99] - Total medical expenses incurred for the current year reached $407,156 million, compared to $235,027 million for the same period in 2023, representing a growth of 73%[102] Cash Flow and Financing - Cash and cash equivalents at the end of the period on June 30, 2024, were $341,069,000, down from $397,008,000 at the end of June 30, 2023, indicating a decrease of approximately 14.1%[35] - The company expects to require additional capital resources to execute strategic initiatives for growth, including technology development and market expansion[185][186] - The company had the option to borrow an additional $35.0 million in undrawn Delayed Draw Term Loans, which expires on September 1, 2025[190] Regulatory Compliance and Risks - The company was in compliance with the minimum capital requirements prescribed by regulatory authorities as of June 30, 2024[132] - The company continues to monitor changes in ownership that could affect the utilization of its substantial NOLs under IRC Section 382[116] Technology and Future Outlook - The company aims to leverage its proprietary technology platform, AVA, to enhance member relationships and care quality, which is expected to drive future performance[146] - The company plans to continue investing in its AVA platform and pursue strategic acquisitions to maintain a differentiated value proposition[153] Other Financial Metrics - The company reported a provision for credit loss of $95,000 for the six months ended June 30, 2024, compared to $51,000 for the same period in 2023, showing an increase of approximately 86.3%[33] - The company recognized a favorable prior year development of $2,460 million for the three months ended June 30, 2024, primarily due to better-than-expected claims recoveries[102]

EXHIBIT 99.1 Alignment Healthcare Reports Second Quarter 2024 Results Reports $681.3 million in total revenue, up 47.3% year-over-year Records strong Medicare Advantage membership growth, up 56.1% year-over-year to approximately 175,100 members, beating expectations Increases year-end membership and revenue guidance, and maintains full-year adjusted gross profit and adjusted EBITDA guidance ORANGE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial ...

Alignment Healthcare, Inc. (NASDAQ:ALHC) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants John Kao - Founder and Chief Executive Officer Thomas Freeman - Chief Financial Officer Conference Call Participants Nathan Rich - Goldman Sachs Ryan Daniels - William Blair John Ransom - Raymond James Adam Ron - Bank of America Whit Mayo - Leerink Partners Jess Tassan - Piper Sandler John Ransom - Raymond James Operator Good afternoon, and welcome to Alignment Healthcare’s First Quarter 202 ...